# Study of STA-1 as an Add-on Treatment to Donepezil

> **NCT01255046** · PHASE2 · UNKNOWN · sponsor: **Sinphar Pharmaceutical Co., Ltd** · enrollment: 136 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Donepezil,
- **DRUG:** STA-1
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01255046
- **Lead sponsor:** Sinphar Pharmaceutical Co., Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-12
- **Primary completion:** 2018-12
- **Final completion:** —
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2014-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01255046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01255046, "Study of STA-1 as an Add-on Treatment to Donepezil". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01255046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*